EUVIMEDEUVIMED entdecken
Crossref

Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?

Revathi Ananthakrishnan, Patrick Mitchell, Dong Xi, Gu Mi, Gina D'Angelo, Haijun Ma, Yujun Wu, Philip He

Therapeutic Innovation & Regulatory Science · 2026

DOI: 10.1007/s43441-026-01010-1 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, 2026. Verfasst von Revathi Ananthakrishnan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Bristol-Myers Squibb (BMS), Princeton, NJ, USA. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Determining the optimal dosage of oncology drugs is a critical component of drug development, as many anticancer agents are associated with high toxicity. With the emergence of targeted therapies and immunotherapies, the conventional concept that “more is better” may not apply, as higher doses do not necessarily yield greater efficacy and may compromise tolerability. In response to repeated post-approval dosage modifications, the U.S. Food and Drug Administration (FDA) launched Project Optimus in 2021 to promote data-driven, patient-centered dosage optimization. Despite the release of the finalized FDA Guidance for Industry on Oncology Dosage Optimization in 2024, sponsors continue to face challenges in translating these recommendations into practice, due to the complexity in the development process of oncology drugs and the limitations of early-phase trials. To gain insight into current practices and challenges, the DahShu Innovative Designs Scientific Working Group (IDSWG) conducted an industry-wide survey among oncology statisticians in biopharmaceutical companies. The survey revealed a shift away from reliance on the maximum tolerated dose toward integrated strategies balancing efficacy, safety, pharmacokinetics, and patient experience. This paper summarizes the findings from that survey and offers practical recommendations emphasizing cross-functional collaboration between statisticians and other functional members in early phase trials, adoption of innovative trial designs, and proactive regulatory engagement regarding dosage optimization strategies in clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic AgentsNeoplasmsHumansUnited StatesMaximum Tolerated DoseUnited States Food and Drug AdministrationDose-Response Relationship, DrugDrug Development

Stichwörter der Autor:innen

Dosage optimizationEfficacyPK/PDPRORandomized trial comparing dosesTotality of dataToxicity

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Bristol-Myers Squibb (BMS), Princeton, NJ, USA.
  • AstraZeneca (AZ), Gaithersburg, MD, USA.
  • Gilead, Foster City, CA, USA.
  • Sanofi, Cambridge, MA, USA.
  • Revolution Medicines, Redwood City, CA, USA.
  • Oncolytics Biotech Inc, San Diego, USA.

Zitieren

APA

Ananthakrishnan, R., Mitchell, P., Xi, D., Mi, G., D'Angelo, G., Ma, H., Wu, Y., & He, P. (2026). Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?. Therapeutic Innovation & Regulatory Science. https://doi.org/10.1007/s43441-026-01010-1

Vancouver

Ananthakrishnan R, Mitchell P, Xi D, Mi G, D'Angelo G, Ma H, et al. Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?. Therapeutic Innovation & Regulatory Science. 2026. doi:10.1007/s43441-026-01010-1

BibTeX
@article{Ananthakrishnan2026,
  author = {Ananthakrishnan, Revathi and Mitchell, Patrick and Xi, Dong and Mi, Gu and D'Angelo, Gina and Ma, Haijun and Wu, Yujun and He, Philip},
  title = {Implementing Project Optimus in Oncology Dosage Optimization: Where are We Now?},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  doi = {10.1007/s43441-026-01010-1}
}
Kostenlos starten →